Early adopters included players for Oklahoma University and San Diego Chargers head coach Sid Gillman, who administered Dianabol to his team starting in 1963. CIBA filed for a U.S. patent in 1957, and began marketing the drug as Dianabol in 1958 in the U.S. Metandienone is subject to extensive hepatic biotransformation by a variety of enzymatic pathways. It is also referred to as methandrostenolone and as dehydromethyltestosterone. The primary urinary metabolites are detectable for up to 3 days, and a recently discovered hydroxymethyl metabolite is found in urine for up to 19 days after a single 5 mg oral dose. The drug is also the 17α-methylated derivative of boldenone (δ1-testosterone) and the δ1 analogue of methyltestosterone (17α-methyltestosterone). Metandienone, also known as 17α-methyl-δ1-testosterone or as 17α-methylandrost-1,4-dien-17β-ol-3-one, is a synthetic androstane steroid and a 17α-alkylated derivative of testosterone. Metandienone, also known as methandienone or methandrostenolone and sold under the brand name Dianabol (D-Bol) among others, is an androgen and anabolic steroid (AAS) medication which is mostly no longer prescribed. While metandienone is controlled and no longer medically available in the U.S., it continues to be produced and used medically in some other countries. Methods for detection in urine specimens usually involve gas chromatography-mass spectrometry. It is a modification of testosterone with a methyl group at the C17α position and an additional double bond between the C1 and C2 positions. The drug is metabolized in the liver by 6β-hydroxylation, 3α- and 3β-oxidation, 5β-reduction, 17-epimerization, and conjugation among other reactions. The elimination half-life of metandienone is about 3 to 6 hours. It has very low affinity for human serum sex hormone-binding globulin (SHBG), about 10% of that of testosterone and 2% of that of DHT. As such, it can cause side effects such as gynecomastia and fluid retention. Methandienone binds to and activates the androgen receptor (AR) in order to exert its effects. Estrogenic side effects such as gynecomastia and fluid retention can also occur. Unlike methyltestosterone, owing to the presence of its C1(2) double bond, metandienone does not produce 5α-reduced metabolites. Proposed metabolism of methyltestosterone (black, … Chemical structures of phase I metabolites of methyltestosterone reported in the literature. The drug is an agonist of the androgen receptor candy96.fun (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT), and has strong anabolic effects and moderate androgenic effects. Reaction scheme for 17α-hydroxymethyl-17β-methyl-18-nor-5ξ-androst-13-en-3ξ-ol steroids. Generic production shut down two years later, when the FDA revoked metandienone's approval entirely in 1985. Following further FDA pressure, CIBA withdrew Dianabol from the U.S. market in 1983. After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the U.S. FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol. During Methandienone treatment, high blood pressure can happen along with fastened heartbeats which may require the administration of antihypertensive drugs. Even a dosage of only 10 mg./day has a noticeable strain on the liver but after the administration is stopped, the liver values return to normal. Although methandienone 10mg has many potential side effects, they are rare with a dosage of up to 20 mg per day. During the treatment period this medicine cases boosted muscle mass, reduce fat deposits, improves trophic tissues, promotes calcium deposits in the bones, retain nitrogen, phosphorus, sulfur, potassium, sodium and water in the body. Synthesis route for 17β-methyl-5β-androstane-3α,17α-diol ( 11 ). Synthesis route for 17β-methyl-5β-androstane-3α,17α-diol ( … The co-administration of an antiestrogen such as an aromatase inhibitor like anastrozole or a selective estrogen receptor modulator like tamoxifen can reduce or prevent such estrogenic side effects. Metandienone is a substrate for aromatase and can be metabolized into the estrogen methylestradiol (17α-methylestradiol). As such, 5α-reductase inhibitors like finasteride and dutasteride do not reduce the androgenic effects of metandienone. As with other 17α-alkylated steroids, methandienone poses a risk of hepatotoxicity and use over extended periods of time can result in liver damage without appropriate precautions. Side effects of metandienone include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire, estrogenic effects like fluid retention and breast enlargement, and liver damage. After the treatment with metandienone, the patients feel a noticeable loss in weight and strength, due to the water excretion from the body, as it was retained in the body during the treatment period. Metandienone therapy requires additional medicines like Tamoxifen and Provimed, as this anabolic medicine is likely to convert into estrogen. The process leads to an increased anabolic activity and inhibits catabolic processes those caused by glucocorticoids. Mass spectrum (GC-EI-QTOF-MS, 70 eV) of 17α-hydroxymethyl-17β-methyl-18-nor-5β-androst-13-en-3α-ol ( 8 ), bis- trimethylsilyl) (TMS… Chemical structures of phase I metabolites of metandienone reported in the literature. Adverse analytical findings of methyltestosterone… In post-administration urines of metandienone, only the 5β-metabolite was detected. Metandienone is an anabolic steroid indicated for appetite stimulation in patients with anorexia. Metandienone is the generic name of the drug and its INNTooltip International Nonproprietary Name, while methandienone is its BANTooltip British Approved Name and métandiénone is its DCFTooltip Dénomination Commune Française.
